# Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

> **NCT05556824** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Microbiome Health Sciences** · enrollment: 247 (estimated)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** MHS-1031
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05556824
- **Lead sponsor:** Microbiome Health Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-03
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 247 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05556824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05556824, "Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05556824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*